FMA
ALDX icon

FNY Managed Accounts’s Aldeyra Therapeutics ALDX Stock Holding History

FNY Managed Accounts’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,000
Closed -$39.1K – 42
2016
Q3 		$39.1K Hold
5,000
– – 0.03% 228
2016
Q2 		$28.4K Sell
5,000
-1,502
-23% -$8.39K 0.03% 150
2016
Q1 		$27.2K Buy
+6,502
New +$31.2K 0.05% 183

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FNY Managed Accounts's ALDX Position: Q4 2016 in Review

FNY Managed Accounts sold out of Aldeyra Therapeutics (ALDX) in Q4 2016, closing a stake of 5,000 shares — an estimated $39.1K sold.

FNY Managed Accounts first reported a position in ALDX in Q1 2016 and held it in 3 quarters. The position peaked at $39.1K in Q3 2016. 20 funds tracked by Wall St. Rank hold ALDX as of Q4 2016.

  • FNY Managed Accounts reported no remaining Aldeyra Therapeutics position as of Q4 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 5,000 Aldeyra Therapeutics shares in Q4 2016, an estimated $39.1K.
  • FNY Managed Accounts first reported a position in Aldeyra Therapeutics in Q1 2016 and held it in 3 quarters.
  • FNY Managed Accounts's Aldeyra Therapeutics position peaked at $39.1K in Q3 2016.
  • 20 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2016.

Based on FNY Managed Accounts's 13F filing for Q4 2016, filed 8 Feb 2017.